Malignant News and Research

RSS

Tumor suppressor, Retinoblastoma, represses DNA replication genes during cellular senescence

A frequently mutated gene in human cancers is the reitnoblastoma (RB) gene, which controls a potent tumor suppression pathway.

15 Apr 2010

Investment report on MIPI

StockPreacher.com announces an investment report featuring Molecular Insight Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

15 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

Phase I clinical trial of DFMO initiated to treat children with neuroblastoma

A new Phase I clinical trial sponsored by the Vermont Cancer Center at the University of Vermont and Fletcher Allen Health Care has opened to test the investigational drug DFMO, or alpha-difluoromethylornithine, as a treatment for the pediatric cancer neuroblastoma.

15 Apr 2010

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.

15 Apr 2010

'Forgotten' cells in brain cancer

Glioblastoma is a guileful enemy. While most of the brain tumor can often be removed surgically, in virtually every case the tumor reappears. One reason for this is that sporadic, infiltrative tumor cells will remain in the brain even after most careful surgery. Researchers at the University of Bonn have now subjected these 'forgotten' cells to closer scrutiny for the first time.

13 Apr 2010

Stress hormones may suppress tumor growth: Study

Chronic stress triggers a chain of molecular events that protects breakaway ovarian cancer cells from destruction, a team of researchers led by scientists at The University of Texas M. D. Anderson Cancer Center reports April 12 in the early online publication of the Journal of Clinical Investigation.

13 Apr 2010

Rosetta Genomics to present posters on microRNA-based technologies at AACR 2010

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today it will present multiple posters at the upcoming American Association of Cancer Research's 101st Annual Meeting to be held at the Walter E. Washington Convention Center in Washington, D.C. from April 17-21, 2010.

12 Apr 2010

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Researchers from Davos Life Science in Singapore, in collaboration with scientists at the University of Hong Kong, have shown that gamma-tocotrienol, a member of the vitamin E family, is potent in killing prostate tumour cells in animal model studies. This research was reported this week in the latest edition of Pharmacology.

9 Apr 2010

Gelatinase B expression enhanced in gastric cancer compared to normal gastric mucosa

Gastric cancer in Mexico is the most frequent gastrointestinal malignant neoplasm. Several precursor conditions, such as chronic gastritis, have been associated with the development of gastric cancer. The gelatinases MMP-2 and MMP-9, members of the metalloproteinase family, are fundamental enzymes in extracellular matrix remodelling. The extracellular matrix is composed of secreted molecules outside cells which provides structural support and regulates cell behaviour.

9 Apr 2010

Researchers show iRGD peptide increases treatment efficacy against cancer

Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.

9 Apr 2010

Bill to stop under 18s using sunbeds passed by the House of Lords

The private member's bill to protect children and teenagers from the dangers of sunbeds was passed today by the House of Lords after Cancer Research UK's campaign.

9 Apr 2010

As overall cancer rates decline in the U.S., thyroid cancer counters the trend

As overall cancer rates are declining in the United States, thyroid cancer counters the trend. It's being diagnosed more frequently, especially in women. Women are three times more likely than men to develop thyroid cancer.

9 Apr 2010

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of a phase III clinical trial of brentuximab vedotin (SGN-35) for post-transplant Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is expressed on malignant Hodgkin lymphoma cells.

8 Apr 2010

Saint Mary's and Sierra Neurosurgery Group partner to create Nevada's first Brain Tumor Center

Saint Mary's and Sierra Neurosurgery Group have partnered to create the region's first Brain Tumor Center in an effort to speed up the time between diagnosis and treatment.

8 Apr 2010

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.

8 Apr 2010

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.

7 Apr 2010

New extra potent sunscreens in the pipeline

Sunscreens are touted to protect your skin from the harmful ultraviolet rays of the sun. However scientists are now studying whether a good sunscreen protects your skin even after your skin is no longer exposed to the sun? This study is undertaken because of the alarming rise in malignant melanoma, a form of skin cancer that is linked to the sun’s UV rays. Malignant melanoma is the most common cancer in Australia and Queensland tops all other places in the world when it comes to incidence of this skin cancer.

7 Apr 2010

Src can be most promising targets for cancer therapy

Src (short for sarcoma) is a family of proto-oncogenic tyrosine kinases active in many cancer tumors, including medulloblastoma, the most common malignant cancer in children. Src represents one of the most promising targets for cancer therapy.

6 Apr 2010

Oncologists to provide overview on new neuro-oncology guidelines

John Theurer Cancer Center at Hackensack University Medical Center will bring together top neuro-oncologists from around the country for an all day symposium to address new treatment updates and review management of complex cases across a broad array of neuro-oncology specialties.

6 Apr 2010